Justin Sharim1, Lori B Daniels2,3. 1. Division of Cardiovascular Medicine, University of California, San Diego, La Jolla, CA, USA. 2. Division of Cardiovascular Medicine, University of California, San Diego, La Jolla, CA, USA. lbdaniels@ucsd.edu. 3. Sulpizio Cardiovascular Center, UC San Diego Health, 9452 Medical Center Drive, La Jolla, CA, 92093-7411, USA. lbdaniels@ucsd.edu.
Abstract
PURPOSE OF REVIEW: Biomarkers of cardiac fibrosis closely track the disease state that gives rise to heart failure. The purpose of this review is to highlight recent data on the use of soluble ST2, galectin-3, and procollagen, three markers of cardiac fibrosis, for aiding with prognostication, and to explore the use of these biomarkers for guiding therapy. RECENT FINDINGS: Soluble ST2, galectin-3, and procollagen are prognostic in both acute and chronic heart failure, and data are emerging as to their potential uses for guiding therapies. Mortality benefit from exercise, cardiac resynchronization therapy, statin use, as well as anti-fibrotic therapies such as aldosterone antagonism may vary based upon levels of these fibrosis markers. Soluble ST2, galectin-3, and procollagen provide independent prognostic information for heart failure morbidity and mortality. Markers of cardiac fibrosis may also help identify the subsets of patients who are most likely to benefit from various therapies. However, further studies are needed prior to formalizing individual patient care algorithms guided by fibrosis biomarkers.
PURPOSE OF REVIEW: Biomarkers of cardiac fibrosis closely track the disease state that gives rise to heart failure. The purpose of this review is to highlight recent data on the use of soluble ST2, galectin-3, and procollagen, three markers of cardiac fibrosis, for aiding with prognostication, and to explore the use of these biomarkers for guiding therapy. RECENT FINDINGS: Soluble ST2, galectin-3, and procollagen are prognostic in both acute and chronic heart failure, and data are emerging as to their potential uses for guiding therapies. Mortality benefit from exercise, cardiac resynchronization therapy, statin use, as well as anti-fibrotic therapies such as aldosterone antagonism may vary based upon levels of these fibrosis markers. Soluble ST2, galectin-3, and procollagen provide independent prognostic information for heart failure morbidity and mortality. Markers of cardiac fibrosis may also help identify the subsets of patients who are most likely to benefit from various therapies. However, further studies are needed prior to formalizing individual patient care algorithms guided by fibrosis biomarkers.
Authors: Zeyu Wang; Xin Pan; Hong Xu; You Wu; Xiaomin Jia; Yiling Fang; Yi Lu; Yawei Xu; Ji Zhang; Yang Su Journal: Front Cardiovasc Med Date: 2022-02-09
Authors: Carles Díez-López; Joel Salazar-Mendiguchía; Elena García-Romero; Lara Fuentes; Josep Lupón; Antoni Bayés-Genis; Nicolás Manito; Marta de Antonio; Pedro Moliner; Elisabet Zamora; Pablo Catalá-Ruiz; Miguel Caínzos-Achirica; Josep Comín-Colet; José González-Costello Journal: J Cardiovasc Dev Dis Date: 2022-01-11